miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. MiRNA based liquid biopsy for castration-resistant prostate cancer diagnostics.Molecular and cellular biochemistry · 2026
   Article
2. Harnessing p53 for targeted cancer therapy: new advances and future directions.Transcription · 2025
   Review
3. A Regulator of Metabolic Reprogramming: MicroRNA Let-7.Translational oncology · 2019
   Article
4. Effects of MiR-107 on The Chemo-drug Sensitivity of Breast Cancer Cells.Open medicine (Warsaw, Poland) · 2019
   Article
5. The progress of circular RNAs in various tumors.American journal of translational research · 2018
   Review

Corrections and comments

• Erratum for
  miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans.2011

Authors and funding

17 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.